medline.ch Onkologie Urologische Tumoren

	Let us trace our path from glass slide to virtual slide and artificial intelligence. Arch Ital Urol Androl Montironi R, Cimadamore A, Trinchieri A. PMID: 42803663 [PubMed - indexed for MEDLINE]
	Global trends and hotspots in bladder cancer: A bibliometric analysis (2016-2025). Urologia Heer R, Farrokhi M. PMID: 42803329 [PubMed - as supplied by publisher]
	Kidney impairment post 177Lu-PSMA radioligand therapy in metastatic prostate cancer. Nucl Med Commun Osbourne J, Hofman MS, Ruderman I. PMID: 42802891 [PubMed - as supplied by publisher]
	Stage migration in prostate cancer: the role of PSMA-PET in identifying oligometastatic disease. Eur J Nucl Med Mol Imaging Mattana F, Luzzago S, Dragonetti V, Kasivisvanathan V, Conlon S, Castellucci P, Farolfi A, Miszczyk M, Techma, Rajwa P, Shariat SF, Zattoni F, Reitano G, Briganti A, Montorsi F, Frassoni S, Bagnardi V, Gandaglia G, Ceci F. PMID: 42802268 [PubMed - as supplied by publisher]
	Androgen Receptor-Immune Crosstalk in Metastatic Castration-Resistant Prostate Cancer: From Context-Dependent Remodeling to Biomarker-Guided Translation. Prostate Li L, Feng R, Zha B, Yang S, Wang G, Jiang Z, Mou J, Gao F. PMID: 42801730 [PubMed - as supplied by publisher]
	Insulin-Like Growth Factor Axis and Survival in Metastatic Hormone-Sensitive Prostate Cancer: Post-Hoc Analysis From the ENZAMET Phase 3 Trial. Prostate Cilento MA, Lin HM, Yeung N, Kim RMN, Portman N, Stockler MR, Martin AJ, Subhash V, Yip S, Butler LM, Marschner IC, Meikle PJ, Azad AA, Davis ID, Horvath LG, Sweeney CJ. PMID: 42801727 [PubMed - as supplied by publisher]
	A Phase II Trial Using Grape Seed Extract for Prostate Cancer Patients With Nonmetastatic Prostate-Specific Antigen Progression After Local Therapy. Mol Carcinog Maroni P, Manalo TA, Baker H, Kessler ER, Nicklawsky A, Trevisanut V, Flaig TW, Lam ET, Moore JC, Gao D, Raina K, Agarwal R. PMID: 42801665 [PubMed - as supplied by publisher]
	Analysis of NAT2 coding variants, combined genotypes, and haplotypes in prostate cancer susceptibility: a case-control study in an Iraqi Arab population. Mol Biol Rep Tarish MA, Kudhair BK. PMID: 42801388 [PubMed - indexed for MEDLINE]
	Plasma circulating tumor deoxyribonucleic acid methylation enables noninvasive disease stratification beyond prostate-specific antigen in prostate cancer. Prostate Int Kim DW, Jung MH, Cho H, Cha J, Han KH, Choi JH, Park M, Park SH, Oh CK, Lee ST, Kim YJ, Chung JS. PMID: 42801146 [PubMed]
	Patients with high-risk features on active surveillance for prostate cancer. Prostate Int Goodman S, Dua Y, Pan HYC, Perera S, Sathianathen N, Perera M, Murphy D, Lawrentschuk N. PMID: 42801144 [PubMed]
	A cfDNA-based DNA methylation classifier for distinguishing prostate cancer from benign prostatic hyperplasia. Prostate Int Lee JH, Oh HJ, Koo HJ, Kim MY, Kim CS, Lim B, Lee JY, Park WY. PMID: 42801083 [PubMed]
	Multicentre evaluation of artificial intelligence risk classification for detection of clinically significant prostate cancer on biparametric MRI. Eur Radiol Guenzel K, Poirot MG, van Loon A, Messina E, Pecoraro M, Panebianco V, Princenthal R, Giganti F. PMID: 42800842 [PubMed - as supplied by publisher]
	A plasma derived hypoxia signature predicts benefit from hypoxia-modifying radiotherapy and reveals dynamic humoral immune modulation in bladder cancer. Br J Cancer Guerrero Quiles C, Abumanhal-Masarweh H, G Abalos J, Lodhi T, Sanchez-Martinez D, Reeves K, James ND, Hall E, Huddart RA, Porta N, Hoskin P, Biolatti LV, Hadjidemetriou M, West CM, Choudhury A. PMID: 42800813 [PubMed - as supplied by publisher]
	Reply to Roberto M. Scarpa's Letter to the Editor re: Paolo Gontero, Richard Perry, Daisy Bridge, et al. Unmet Treatment Need and Challenges Associated with Comparative Evidence Generation in BCG-unresponsive Non-muscle-invasive Bladder Cancer: An Expert Consensus. Eur Urol Oncol 2026;9(3):652-9. Eur Urol Oncol Gontero P, Babjuk M. PMID: 42800742 [PubMed - as supplied by publisher]
	Primary ALK-positive anaplastic large cell lymphoma of the urinary bladder in a pediatric patient: a case report and review of literature. J Hematop Kaur N, Aravind A, Jain SP. PMID: 42799861 [PubMed - indexed for MEDLINE]
	Identification and experimental validation of prognostic genes associated with dietary restriction-related signatures in bladder cancer. Front Immunol Wu X, Sun T, Liu Z. PMID: 42798489 [PubMed - indexed for MEDLINE]
	Repurposing a prostate tumor marker: elevated FPSA/TPSA ratio as a novel non-invasive biomarker for declining eGFR in male type 2 diabetes. Front Endocrinol (Lausanne) Zhao S, Hu H, Zhao X, Zhang L, Niu D. PMID: 42798458 [PubMed - indexed for MEDLINE]
	Plasma exosomal lncRNA SLC16A1-AS1 as an early diagnostic biomarker for renal cell carcinoma. Front Oncol Sun Y, Li Z, Ren C, Wang D, Zhu X. PMID: 42798305 [PubMed]
	Trial design drives outcomes: harmonising efficacy across BCG-unresponsive bladder carcinoma inÂ situ trials. BJU Int Robesti D, Kamat AM, Ploussard G, Contieri R, Fallara G, Briganti A, Montorsi F, van der Heijden AG, Malavaud B, Pohar K, Shore N, Dinney CPN, Martini A. PMID: 42798234 [PubMed - as supplied by publisher]
	Retzius-Sparing Robot-Assisted Radical Prostatectomy: Analysis of Functional and Oncological Outcomes. Medicina (Kaunas) Akdeniz F, Ün S, Boylu U, Köseler A. PMID: 42796398 [PubMed - indexed for MEDLINE]

Artikel 1 - 20 / 181762

Seite 1 von 9089

Suchbegriffe

Benutzen Sie englische Suchbegriffe für Ihre Suche in medline.ch.

Übersetzungsproblem?

mehr >>



		Zeitfenster

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Datenschutzerklärung / Privacy Policy \| Werbung